Business Description
Gland Pharma Ltd
ISIN : INE068V01023
Compare
Compare
Traded in other countries / regions
GLAND.India IPO Date
2020-11-20Description
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.97 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.22 | |||||
| Interest Coverage | 39.91 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 9.86 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.6 | |||||
| 3-Year EBITDA Growth Rate | 0.1 | |||||
| 3-Year EPS without NRI Growth Rate | -9.2 | |||||
| 3-Year FCF Growth Rate | 15.2 | |||||
| 3-Year Book Growth Rate | 13.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 18.67 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.89 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.29 | |||||
| 9-Day RSI | 54.69 | |||||
| 14-Day RSI | 53.42 | |||||
| 6-1 Month Momentum % | -0.65 | |||||
| 12-1 Month Momentum % | 4.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.16 | |||||
| Quick Ratio | 3.14 | |||||
| Cash Ratio | 1.9 | |||||
| Days Inventory | 276.63 | |||||
| Days Sales Outstanding | 91.69 | |||||
| Days Payable | 147.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.14 | |||||
| Dividend Payout Ratio | 0.47 | |||||
| Forward Dividend Yield % | 1.14 | |||||
| 5-Year Yield-on-Cost % | 1.1 | |||||
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 0.55 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.15 | |||||
| Operating Margin % | 15.35 | |||||
| Net Margin % | 11.79 | |||||
| FCF Margin % | 10.2 | |||||
| ROE % | 8.04 | |||||
| ROA % | 6.52 | |||||
| ROIC % | 8.19 | |||||
| 3-Year ROIIC % | -5.36 | |||||
| ROC (Joel Greenblatt) % | 17.83 | |||||
| ROCE % | 11.84 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 41.87 | |||||
| Forward PE Ratio | 36.05 | |||||
| PE Ratio without NRI | 41.61 | |||||
| Price-to-Owner-Earnings | 35.16 | |||||
| PEG Ratio | 3.72 | |||||
| PS Ratio | 4.93 | |||||
| PB Ratio | 3.29 | |||||
| Price-to-Tangible-Book | 3.44 | |||||
| Price-to-Free-Cash-Flow | 48.4 | |||||
| Price-to-Operating-Cash-Flow | 29.06 | |||||
| EV-to-EBIT | 24.53 | |||||
| EV-to-EBITDA | 18.1 | |||||
| EV-to-Revenue | 4.51 | |||||
| EV-to-FCF | 44.58 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.34 | |||||
| Price-to-Graham-Number | 2.52 | |||||
| Price-to-Net-Current-Asset-Value | 6.7 | |||||
| Price-to-Net-Cash | 34.03 | |||||
| Earnings Yield (Greenblatt) % | 4.07 | |||||
| FCF Yield % | 2.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gland Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 58,671.58 | ||
| EPS (TTM) (₹) | 41.99 | ||
| Beta | 0.56 | ||
| Volatility % | 33.82 | ||
| 14-Day RSI | 53.42 | ||
| 14-Day ATR (₹) | 65.321091 | ||
| 20-Day SMA (₹) | 1689.47 | ||
| 12-1 Month Momentum % | 4.47 | ||
| 52-Week Range (₹) | 1590 - 2220.95 | ||
| Shares Outstanding (Mil) | 164.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gland Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gland Pharma Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gland Pharma Ltd Frequently Asked Questions
What is Gland Pharma Ltd(BOM:543245)'s stock price today?
The current price of BOM:543245 is ₹1761.95. The 52 week high of BOM:543245 is ₹2220.95 and 52 week low is ₹1590.00.
When is next earnings date of Gland Pharma Ltd(BOM:543245)?
The next earnings date of Gland Pharma Ltd(BOM:543245) is 2025-02-14 Est..
Does Gland Pharma Ltd(BOM:543245) pay dividends? If so, how much?
The Dividend Yield %  of Gland Pharma Ltd(BOM:543245) is 1.14% (As of Today), Highest Dividend Payout Ratio of Gland Pharma Ltd(BOM:543245) was 0.47. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Gland Pharma Ltd(BOM:543245) is 1.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers